Rapid Therapeutic Science Laboratories, Inc. (RTSL)
Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. This innovative approach is aimed at treating various conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. RTSL's product portfolio features pressurized meter dose inhalers (MDIs), designed to precisely dispense an aerosolized mist into the lungs, alongside sublingual oral spray devices. Furthermore, the company offers water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its "nhaler" brand. Established in 2013 and based in Dallas, Texas, the company adopted its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, having previously operated as Holly Brothers Pictures, Inc. It was also formerly a subsidiary of Texas Mdi, Inc.
Sector: Medical - Pharmaceuticals
Industry: Medical - Pharmaceuticals
Rapid Therapeutic Science Laboratories, Inc.
- Not computed yet: no FINRA short interest has been matched to this float.
- 10.7M
- 2.18
Float 3.69M · FMP free float
The cost to borrow RTSL shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- No fails on record for 16–31 Oct 2026.
No price or settlement history available to chart.
FINRA publishes no off-exchange short volume for this symbol.
FINRA's weekly alternative trading system (dark pool) volume for RTSL: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.